Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening?
Introduction: Cirrhosis and liver cancer are currently common causes of death worldwide. The global epidemic of obesity has increased the incidence of nonalcoholic fatty liver disease (NAFLD) and cirrhosis in recent years. Advanced fibrosis increases the morbimortality rate in NAFLD. The Mexican pop...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-05-01
|
| Series: | Annals of Hepatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268120300077 |
| _version_ | 1819101205017657344 |
|---|---|
| author | Diego García-Compeán Jesús Zacarías Villarreal-Pérez Manuel Enrique de la O. Cavazos Fernando Javier Lavalle-Gonzalez Omar David Borjas-Almaguer Angel Noé Del Cueto-Aguilera José Alberto González-González Consuelo Treviño-Garza Lourdes Huerta-Pérez Héctor Jesús Maldonado-Garza |
| author_facet | Diego García-Compeán Jesús Zacarías Villarreal-Pérez Manuel Enrique de la O. Cavazos Fernando Javier Lavalle-Gonzalez Omar David Borjas-Almaguer Angel Noé Del Cueto-Aguilera José Alberto González-González Consuelo Treviño-Garza Lourdes Huerta-Pérez Héctor Jesús Maldonado-Garza |
| author_sort | Diego García-Compeán |
| collection | DOAJ |
| description | Introduction: Cirrhosis and liver cancer are currently common causes of death worldwide. The global epidemic of obesity has increased the incidence of nonalcoholic fatty liver disease (NAFLD) and cirrhosis in recent years. Advanced fibrosis increases the morbimortality rate in NAFLD. The Mexican population has one of the highest prevalence of obesity and diabetes mellitus (DM) worldwide. Aim: To determine the prevalence of advanced liver fibrosis in Mexican general population. Methods: Adult individuals, without a history of liver disease nor heavy alcohol consumption were randomly sampled from 20,919 participants of a health and nutrition survey applied to the general population. Clinical and laboratory evaluations were performed to calculate the NAFLD fibrosis score (NFS) (an extensively validated non-invasive method). Two cut-off points were used. Advanced fibrosis was defined as a result >0.676. Results: In total 695 individuals were included. The mean age was 47.8 ± 16.4. The majority were between 20 and 50 years (59%), 70.2% were female, 35.5% showed obesity and 15.8% DM. The 93% had normal serum ALT. Based on the NFS results, 56 individuals (8.1%) had a high probability of fibrosis. Most patients from this subgroup showed normal serum ALT (92.9%), 89.3% were >45 yr. old, 52% were obese and 27% suffered from DM. Conclusions: Based on these results, 8.1% of Mexican general population without a history of liver disease is at high risk of having advanced liver fibrosis and complications and death derived from cardiovascular disease and cirrhosis. Most of them showed normal ALT serum levels. |
| first_indexed | 2024-12-22T01:14:58Z |
| format | Article |
| id | doaj.art-b999cb5c27f243e7850ccbc529487fb1 |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-12-22T01:14:58Z |
| publishDate | 2020-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-b999cb5c27f243e7850ccbc529487fb12022-12-21T18:43:54ZengElsevierAnnals of Hepatology1665-26812020-05-01193258264Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening?Diego García-Compeán0Jesús Zacarías Villarreal-Pérez1Manuel Enrique de la O. Cavazos2Fernando Javier Lavalle-Gonzalez3Omar David Borjas-Almaguer4Angel Noé Del Cueto-Aguilera5José Alberto González-González6Consuelo Treviño-Garza7Lourdes Huerta-Pérez8Héctor Jesús Maldonado-Garza9Gastroenterology Service, Internal Medicine Department, University Hospital and Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, N.L., Mexico; Corresponding author.Endocrinology Service, Internal Medicine Department, University Hospital and Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, N.L., MexicoDepartment of Pediatric, University Hospital and Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, N.L., Mexico; Ministry of Health of the Government of the State of Nuevo León, Monterrey, N.L., MexicoEndocrinology Service, Internal Medicine Department, University Hospital and Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, N.L., MexicoGastroenterology Service, Internal Medicine Department, University Hospital and Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, N.L., MexicoGastroenterology Service, Internal Medicine Department, University Hospital and Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, N.L., MexicoGastroenterology Service, Internal Medicine Department, University Hospital and Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, N.L., MexicoDepartment of Pediatric, University Hospital and Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, N.L., Mexico; Ministry of Health of the Government of the State of Nuevo León, Monterrey, N.L., MexicoFaculty of Public Health and Nutrition, Autonomous University of Nuevo León, Monterrey, N.L., Mexico; Ministry of Health of the Government of the State of Nuevo León, Monterrey, N.L., MexicoGastroenterology Service, Internal Medicine Department, University Hospital and Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, N.L., MexicoIntroduction: Cirrhosis and liver cancer are currently common causes of death worldwide. The global epidemic of obesity has increased the incidence of nonalcoholic fatty liver disease (NAFLD) and cirrhosis in recent years. Advanced fibrosis increases the morbimortality rate in NAFLD. The Mexican population has one of the highest prevalence of obesity and diabetes mellitus (DM) worldwide. Aim: To determine the prevalence of advanced liver fibrosis in Mexican general population. Methods: Adult individuals, without a history of liver disease nor heavy alcohol consumption were randomly sampled from 20,919 participants of a health and nutrition survey applied to the general population. Clinical and laboratory evaluations were performed to calculate the NAFLD fibrosis score (NFS) (an extensively validated non-invasive method). Two cut-off points were used. Advanced fibrosis was defined as a result >0.676. Results: In total 695 individuals were included. The mean age was 47.8 ± 16.4. The majority were between 20 and 50 years (59%), 70.2% were female, 35.5% showed obesity and 15.8% DM. The 93% had normal serum ALT. Based on the NFS results, 56 individuals (8.1%) had a high probability of fibrosis. Most patients from this subgroup showed normal serum ALT (92.9%), 89.3% were >45 yr. old, 52% were obese and 27% suffered from DM. Conclusions: Based on these results, 8.1% of Mexican general population without a history of liver disease is at high risk of having advanced liver fibrosis and complications and death derived from cardiovascular disease and cirrhosis. Most of them showed normal ALT serum levels.http://www.sciencedirect.com/science/article/pii/S1665268120300077NAFLDNAFLD fibrosis scoreAdvanced liver fibrosisScreening fibrosisGeneral population |
| spellingShingle | Diego García-Compeán Jesús Zacarías Villarreal-Pérez Manuel Enrique de la O. Cavazos Fernando Javier Lavalle-Gonzalez Omar David Borjas-Almaguer Angel Noé Del Cueto-Aguilera José Alberto González-González Consuelo Treviño-Garza Lourdes Huerta-Pérez Héctor Jesús Maldonado-Garza Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening? Annals of Hepatology NAFLD NAFLD fibrosis score Advanced liver fibrosis Screening fibrosis General population |
| title | Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening? |
| title_full | Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening? |
| title_fullStr | Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening? |
| title_full_unstemmed | Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening? |
| title_short | Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening? |
| title_sort | prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus time for screening |
| topic | NAFLD NAFLD fibrosis score Advanced liver fibrosis Screening fibrosis General population |
| url | http://www.sciencedirect.com/science/article/pii/S1665268120300077 |
| work_keys_str_mv | AT diegogarciacompean prevalenceofliverfibrosisinanunselectedgeneralpopulationwithhighprevalenceofobesityanddiabetesmellitustimeforscreening AT jesuszacariasvillarrealperez prevalenceofliverfibrosisinanunselectedgeneralpopulationwithhighprevalenceofobesityanddiabetesmellitustimeforscreening AT manuelenriquedelaocavazos prevalenceofliverfibrosisinanunselectedgeneralpopulationwithhighprevalenceofobesityanddiabetesmellitustimeforscreening AT fernandojavierlavallegonzalez prevalenceofliverfibrosisinanunselectedgeneralpopulationwithhighprevalenceofobesityanddiabetesmellitustimeforscreening AT omardavidborjasalmaguer prevalenceofliverfibrosisinanunselectedgeneralpopulationwithhighprevalenceofobesityanddiabetesmellitustimeforscreening AT angelnoedelcuetoaguilera prevalenceofliverfibrosisinanunselectedgeneralpopulationwithhighprevalenceofobesityanddiabetesmellitustimeforscreening AT josealbertogonzalezgonzalez prevalenceofliverfibrosisinanunselectedgeneralpopulationwithhighprevalenceofobesityanddiabetesmellitustimeforscreening AT consuelotrevinogarza prevalenceofliverfibrosisinanunselectedgeneralpopulationwithhighprevalenceofobesityanddiabetesmellitustimeforscreening AT lourdeshuertaperez prevalenceofliverfibrosisinanunselectedgeneralpopulationwithhighprevalenceofobesityanddiabetesmellitustimeforscreening AT hectorjesusmaldonadogarza prevalenceofliverfibrosisinanunselectedgeneralpopulationwithhighprevalenceofobesityanddiabetesmellitustimeforscreening |